Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 Injection in Patients With Chronic Hepatitis B

NCT07673068 is registered in ClinicalTrials.gov with Grand Theravac Life Sciences (Nanjing) Co., Ltd. as lead sponsor.

NCT NCT07673068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07673068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TVAX-028 Injection in Patients With Chronic Hepatitis B
Lead sponsor
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2027
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hbv infection